What types of diseases does Teclistamab-cqyv mainly treat?

Teritusumab（Teclistamab-cqyv) is an innovative bispecificT cell-linked monoclonal antibody, developed by Johnson & Johnson (Janssen Biotech). It is mainly used to treat relapsed or refractory multiple myeloma（relapsed/refractory multiple myeloma, RRMM). As a highly targeted immunotherapy drug, teritusumab combines with B cell maturation antigen (BCMA) and T cell surface marker CD3 to accurately guide T cells to myeloma cells, thereby inducing the latter to be eliminated by T cells.

Multiple myeloma is a malignant hematological disease derived from plasma cells. Its pathogenesis is closely related to abnormalities in the immune microenvironment. Although traditional treatments such as proteasome inhibitors, immunomodulators, and monoclonal antibodies can temporarily control the disease, most patients will eventually relapse or become drug-resistant. The emergence of teritusumab marks a critical step in the treatment of multiple myeloma with bispecific antibodies, especially providing a new option for patients who have no drug available after multiple lines of treatment.

From a mechanistic point of view,BCMA is an antigen that is highly expressed on the surface of myeloma cells, while CD3 is the core signaling molecule for T cell activation. Teritusumab connects these two targets, causing T cells to form an immune synapse with tumor cells, stimulating the cytotoxicity of T cells and releasing cytokines such as perforin and granzymes, thereby killing myeloma cells. Unlike CAR-T cell therapy, teritusumab is an off-the-shelf drug that does not need to be customized for each patient. It has a faster treatment start time and wider applicability.

It is worth noting that despite its remarkable efficacy, immune-related adverse reactions may occur during use, such as cytokine release syndrome (CRS), neurotoxicity, etc. Therefore, the drug must be administered in an experienced medical institution, and a dose-by-dose ascending guided dose procedure should be followed to reduce the risk of side effects.

Reference materials:https://www.tecvayli.com/